Nektar Therapeutics (NKTR)
70.70
-1.38
(-1.91%)
USD |
NASDAQ |
Mar 26, 13:35
Nektar Therapeutics Cash from Investing (Quarterly) : 0.372M for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Boston Scientific Corp. | -512.00M |
| Eli Lilly & Co. | -2.802B |
| Rigel Pharmaceuticals, Inc. | -25.36M |
| Esperion Therapeutics, Inc. | 0.00 |
| Insmed, Inc. | 389.41M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -64.96M |
| Cash from Financing (Quarterly) | 38.67M |
| Free Cash Flow | -208.68M |
| Free Cash Flow Per Share (Quarterly) | -3.201 |
| Free Cash Flow to Equity (Quarterly) | -46.81M |
| Free Cash Flow to Firm (Quarterly) | -55.20M |
| Free Cash Flow Yield | -4.47% |